eprosartan


Also found in: Dictionary, Wikipedia.
Related to eprosartan: eprosartan mesylate

eprosartan

 [ep″ro-sar´tan]
an angiotensin II antagonist that causes vasodilation and decreases the effects of aldosterone; used as an antihypertensive, administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

eprosartan

(ep-roe-sar-tan) ,

Teveten

(trade name)

Classification

Therapeutic: antihypertensives
Pharmacologic: angiotensin ii receptor antagonists
Pregnancy Category: D

Indications

Alone or with other agents in the management of hypertension.

Action

Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II at various receptor sites, including vascular smooth muscle and the adrenal glands.

Therapeutic effects

Lowering of BP in patients with hypertension.

Pharmacokinetics

Absorption: 13% absorbed following oral administration.
Distribution: Crosses the placenta.
Protein Binding: 98%.
Metabolism and Excretion: Excreted mostly unchanged in feces via biliary excretion.
Half-life: 20 hr.

Time/action profile (antihypertensive effect with chronic dosing)

ROUTEONSETPEAKDURATION
POwithin 1–2 hr2–3 wksr24 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Concurrent use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (CCr <60 mL/min) Obstetric: Can cause injury or death of fetus – if pregnancy occurs, discontinue immediately. Lactation: Discontinue drug or use formula.
Use Cautiously in: Volume- or salt-depleted patients or patients receiving large doses of diuretics (correct deficits before initiating therapy); genetic implication Black patients (may not be as effective); Impaired renal function caused by primary renal disease or heart failure (may worsen renal function); Women of childbearing potential; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • depression
  • fatigue

Cardiovascular

  • hypotension

Ear, Eye, Nose, Throat

  • pharyngitis
  • rhinitis

Fluid and Electrolyte

  • hyperkalemia

Gastrointestinal

  • abdominal pain

Genitourinary

  • impaired renal function

Musculoskeletal

  • pain

Miscellaneous

  • angioedema (life-threatening)

Interactions

Drug-Drug interaction

Additive hypotension with other antihypertensives.Excessive hypotension may occur with concurrent use of diuretics.↑ risk of hyperkalemia with concurrent use of potassium supplements,potassium-containing salt substitutes, or potassium-sparing diuretics.↑ risk of hyperkalemia, renal dysfunction, hypotension, and syncope with concurrent use of ACE inhibitors or aliskiren ; avoid concurrent use with aliskiren in patients with diabetes or CCr <60 mL/minNSAIDs and selective COX-2 inhibitors may blunt the antihypertensive effect and ↑ the risk of renal dysfunction.

Route/Dosage

Oral (Adults) 600 mg once daily when used as monotherapy in patients who are not volume depleted; may be ↑ to 800 mg/day (in 1–2 divided doses).

Renal Impairment

Oral (Adults) CCr <60 mL/min—Do not exceed 600 mg/day.

Availability (generic available)

Tablets: 400 mg, 600 mg
In combination with: hydrochlorothiazide (Teveten HCT; see combination drugs).

Nursing implications

Nursing assessment

  • Assess BP (lying, sitting, standing) and pulse frequently during initial dosage adjustment and periodically throughout therapy. Notify health care professional of significant changes.
  • Monitor frequency of prescription refills to determine compliance.
  • Assess patients for signs of angioedema (dyspnea, facial swelling). May rarely cause angioedema.
  • Lab Test Considerations: Monitor renal function. May cause increase in BUN and serum creatinine.
    • May cause hyperkalemia.
    • May cause elevated AST, ALT, and alkaline phosphatase.
    • May cause slight decrease in hemoglobin, neutropenia, or thrombocytopenia.

Potential Nursing Diagnoses

Risk for injury (Adverse Reactions)
Noncompliance (Patient/Family Teaching)

Implementation

  • Volume depletion should be corrected, if possible, before initiation of therapy.
  • Oral: May be administered without regard to meals.

Patient/Family Teaching

  • Emphasize the importance of continuing to take as directed, even if feeling well. Take missed doses as soon as remembered if not almost time for next dose; do not double doses. Instruct patient to take medication at the same time each day. Warn patient not to discontinue therapy unless directed by health care professional.
  • Caution patient to avoid salt substitutes containing potassium or foods containing high levels of potassium or sodium unless directed by health care professional. See.
  • Encourage patient to comply with additional interventions for hypertension (weight reduction, low-sodium diet, discontinuation of smoking, moderation of alcohol consumption, regular exercise, stress management). Medication controls but does not cure hypertension.
  • Instruct patient and family on proper technique for monitoring BP. Advise them to check BP at least weekly and to report significant changes.
  • Caution patient to avoid sudden changes in position to decrease orthostatic hypotension. Use of alcohol, standing for long periods, exercising, and hot weather may increase orthostatic hypotension.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications, especially cough, cold, or allergy remedies.
  • Instruct patient to notify health care professional of medication regimen before treatment or surgery.
  • Instruct patient to notify health care professional if swelling of face, eyes, lips, or tongue or if difficulty swallowing or breathing occur.
  • Advise women of childbearing age to use contraception and notify health care professional if pregnancy is suspected or planned, or if breastfeeding. If pregnancy is detected, discontinue medication as soon as possible. Avoid breastfeeding.
  • Emphasize the importance of follow-up exams to evaluate effectiveness of medication.

Evaluation/Desired Outcomes

  • Decrease in BP without appearance of excessive side effects.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Eprosartan may be associated with rare instances of hepatotoxicity that typically occurs within 2-16 weeks of therapy.
Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan. Cesk Patol.
Eprosartan Mesylate Mylan Pharmaceuticals Teveten tablets
TYPES AND FUNCTIONS OF BLOOD PRESSURE DRUGS TYPE GENERIC NAME FUNCTION (BRAND NAME) Diuretics Furosemide Help rid the body of (Lasix) excess sodium and water Chlorthalidone (Hygroton) Beta blockers Acebutolol Reduce the heart rate, (Sectral) the heart's workload and its output of blood Atenolol (Tenormin) Betaxolol (Kerlone) Angiotensin-converting Ramipril Help reduce the enzyme (ACE) inhibitors (Altace) production of angiotensin, which causes blood vessels to narrow Benazepril hydrochloride (Lotensin) Angiotensin II receptor Irbesarten Help prevent the blockers (ARBs) (Avapro) receptors in blood vessels from binding with angiotensin Eprosartan mesylate (Teveten) Valsartan (Diovan)
Morbidity and mortality after stroke eprosartan compared compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
28 December 2011 - US generic and specialty pharmaceutical major Mylan Inc (NASDAQ:MYL) said on Tuesday its Mylan Pharmaceuticals Inc unit had obtained final US Food and Drug Administration (FDA) approval for its ANDA for Eprosartan Mesylate Tablets, 400 mg (base) and 600 mg (base), the generic version of Abbott's (NYSE:ABT) hypertension treatment Teveten Tablets.
There are seven single-ingredient ARBs approved by the FDA for treating hypertension: candesartan (Atacand), irbesartan (Avapro), olmesartan (Benicar), losartan (Cozaar), valsartan (Diovan), telmisartan (Micardis), and eprosartan (Teveten).
The key words used for search were: congestive heart failure, chronic heart failure, heart failure, left ventricular systolic dysfunction, Angiotensin converting enzyme inhibitors, angiotensin- II receptor blockers, angiotensin receptor blockers, combination angiotensin converting enzyme inhibitors and angiotensin- II receptor blockers (or angiotensin receptor blockers) and the following generic names of individual agents in current practice: candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, and valsartan.
Two simple and accurate spectrophotometric methods were presented for the determination of binary mixtures of each of Eprosartan and Irbesartan with Hydrochlorothiazide in dosage forms.
Teveten(R) HCT is a combination of the angiotensin II receptor blocker (ARB), eprosartan mesylate, and the diuretic, hydrochlorothiazide.